Cargando…

Characterization and clinical enrichment of HLA-C*07:02-restricted Cytomegalovirus-specific CD8(+) T cells

Human Cytomegalovirus (CMV) reactivation remains a major source of morbidity in patients after solid organ and hematopoietic stem cell transplantation (HSCT). Adoptive T cell therapy (ACT) with CMV-specific T cells is a promising therapeutic approach for HSCT recipients, but might be counteracted by...

Descripción completa

Detalles Bibliográficos
Autores principales: Schlott, Fabian, Steubl, Dominik, Ameres, Stefanie, Moosmann, Andreas, Dreher, Stefan, Heemann, Uwe, Hösel, Volker, Busch, Dirk H., Neuenhahn, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5831000/
https://www.ncbi.nlm.nih.gov/pubmed/29489900
http://dx.doi.org/10.1371/journal.pone.0193554
_version_ 1783303106461696000
author Schlott, Fabian
Steubl, Dominik
Ameres, Stefanie
Moosmann, Andreas
Dreher, Stefan
Heemann, Uwe
Hösel, Volker
Busch, Dirk H.
Neuenhahn, Michael
author_facet Schlott, Fabian
Steubl, Dominik
Ameres, Stefanie
Moosmann, Andreas
Dreher, Stefan
Heemann, Uwe
Hösel, Volker
Busch, Dirk H.
Neuenhahn, Michael
author_sort Schlott, Fabian
collection PubMed
description Human Cytomegalovirus (CMV) reactivation remains a major source of morbidity in patients after solid organ and hematopoietic stem cell transplantation (HSCT). Adoptive T cell therapy (ACT) with CMV-specific T cells is a promising therapeutic approach for HSCT recipients, but might be counteracted by CMV’s immune evasion strategies. HLA-C*07:02 is less susceptible to viral immune evasion suggesting HLA-C*07:02-restricted viral epitopes as promising targets for ACT. For a better understanding of HLA-C*07:02-restricted CMV-specific T cells we used recently generated reversible HLA-C*07:02/IE-1 multimers (Streptamers) recognizing a CMV-derived Immediate-Early-1 (IE-1) epitope and analyzed phenotypic and functional T cell characteristics. Initially, we detected very high frequencies of HLA-C*07:02/IE-1 multimer(+) T cells (median = 11.35%), as well as robust functional responses after stimulation with IE-1 peptide (IFNγ(+); median = 5.02%) in healthy individuals. However, MHC-multimer(+) and IFNγ-secreting T cell frequencies showed a relatively weak correlation (r(2) = 0.77), which could be attributed to an unexpected contribution of CMV-epitope-independent KIR2DL2/3-binding of HLA-C*07:02/IE-1 multimers. Therefore, we developed a MHC-multimer double-staining approach against a cancer epitope-specific HLA-C*07:02 multimer to identify truly HLA-C*07:02/IE-1 epitope-specific T cells. The frequencies of these truly HLA-C*07:02/IE-1 multimer(+) T cells were still high (median = 6.86%) and correlated now strongly (r(2) = 0.96) with IFNγ-secretion. Interestingly, HLA-C*07:02/IE-1-restricted T cells contain substantial numbers with a central memory T cell phenotype, indicating high expansion potential e.g. for ACT. In line with that, we developed a clinical enrichment protocol avoiding epitope-independent KIR-binding to make HLA-C*07:02/IE-1-restricted T cells available for ACT. Initial depletion of KIR-expressing CD8(+) T cells followed by HLA-C*07:02/IE-1 Streptamer positive selection using paramagnetic labeling techniques allowed to enrich successfully HLA-C*07:02/IE-1-restricted T cells. Such specifically enriched populations of functional HLA-C*07:02/IE-1-restricted T cells with significant central memory T cell content could become a potent source for ACT.
format Online
Article
Text
id pubmed-5831000
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-58310002018-03-19 Characterization and clinical enrichment of HLA-C*07:02-restricted Cytomegalovirus-specific CD8(+) T cells Schlott, Fabian Steubl, Dominik Ameres, Stefanie Moosmann, Andreas Dreher, Stefan Heemann, Uwe Hösel, Volker Busch, Dirk H. Neuenhahn, Michael PLoS One Research Article Human Cytomegalovirus (CMV) reactivation remains a major source of morbidity in patients after solid organ and hematopoietic stem cell transplantation (HSCT). Adoptive T cell therapy (ACT) with CMV-specific T cells is a promising therapeutic approach for HSCT recipients, but might be counteracted by CMV’s immune evasion strategies. HLA-C*07:02 is less susceptible to viral immune evasion suggesting HLA-C*07:02-restricted viral epitopes as promising targets for ACT. For a better understanding of HLA-C*07:02-restricted CMV-specific T cells we used recently generated reversible HLA-C*07:02/IE-1 multimers (Streptamers) recognizing a CMV-derived Immediate-Early-1 (IE-1) epitope and analyzed phenotypic and functional T cell characteristics. Initially, we detected very high frequencies of HLA-C*07:02/IE-1 multimer(+) T cells (median = 11.35%), as well as robust functional responses after stimulation with IE-1 peptide (IFNγ(+); median = 5.02%) in healthy individuals. However, MHC-multimer(+) and IFNγ-secreting T cell frequencies showed a relatively weak correlation (r(2) = 0.77), which could be attributed to an unexpected contribution of CMV-epitope-independent KIR2DL2/3-binding of HLA-C*07:02/IE-1 multimers. Therefore, we developed a MHC-multimer double-staining approach against a cancer epitope-specific HLA-C*07:02 multimer to identify truly HLA-C*07:02/IE-1 epitope-specific T cells. The frequencies of these truly HLA-C*07:02/IE-1 multimer(+) T cells were still high (median = 6.86%) and correlated now strongly (r(2) = 0.96) with IFNγ-secretion. Interestingly, HLA-C*07:02/IE-1-restricted T cells contain substantial numbers with a central memory T cell phenotype, indicating high expansion potential e.g. for ACT. In line with that, we developed a clinical enrichment protocol avoiding epitope-independent KIR-binding to make HLA-C*07:02/IE-1-restricted T cells available for ACT. Initial depletion of KIR-expressing CD8(+) T cells followed by HLA-C*07:02/IE-1 Streptamer positive selection using paramagnetic labeling techniques allowed to enrich successfully HLA-C*07:02/IE-1-restricted T cells. Such specifically enriched populations of functional HLA-C*07:02/IE-1-restricted T cells with significant central memory T cell content could become a potent source for ACT. Public Library of Science 2018-02-28 /pmc/articles/PMC5831000/ /pubmed/29489900 http://dx.doi.org/10.1371/journal.pone.0193554 Text en © 2018 Schlott et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Schlott, Fabian
Steubl, Dominik
Ameres, Stefanie
Moosmann, Andreas
Dreher, Stefan
Heemann, Uwe
Hösel, Volker
Busch, Dirk H.
Neuenhahn, Michael
Characterization and clinical enrichment of HLA-C*07:02-restricted Cytomegalovirus-specific CD8(+) T cells
title Characterization and clinical enrichment of HLA-C*07:02-restricted Cytomegalovirus-specific CD8(+) T cells
title_full Characterization and clinical enrichment of HLA-C*07:02-restricted Cytomegalovirus-specific CD8(+) T cells
title_fullStr Characterization and clinical enrichment of HLA-C*07:02-restricted Cytomegalovirus-specific CD8(+) T cells
title_full_unstemmed Characterization and clinical enrichment of HLA-C*07:02-restricted Cytomegalovirus-specific CD8(+) T cells
title_short Characterization and clinical enrichment of HLA-C*07:02-restricted Cytomegalovirus-specific CD8(+) T cells
title_sort characterization and clinical enrichment of hla-c*07:02-restricted cytomegalovirus-specific cd8(+) t cells
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5831000/
https://www.ncbi.nlm.nih.gov/pubmed/29489900
http://dx.doi.org/10.1371/journal.pone.0193554
work_keys_str_mv AT schlottfabian characterizationandclinicalenrichmentofhlac0702restrictedcytomegalovirusspecificcd8tcells
AT steubldominik characterizationandclinicalenrichmentofhlac0702restrictedcytomegalovirusspecificcd8tcells
AT ameresstefanie characterizationandclinicalenrichmentofhlac0702restrictedcytomegalovirusspecificcd8tcells
AT moosmannandreas characterizationandclinicalenrichmentofhlac0702restrictedcytomegalovirusspecificcd8tcells
AT dreherstefan characterizationandclinicalenrichmentofhlac0702restrictedcytomegalovirusspecificcd8tcells
AT heemannuwe characterizationandclinicalenrichmentofhlac0702restrictedcytomegalovirusspecificcd8tcells
AT hoselvolker characterizationandclinicalenrichmentofhlac0702restrictedcytomegalovirusspecificcd8tcells
AT buschdirkh characterizationandclinicalenrichmentofhlac0702restrictedcytomegalovirusspecificcd8tcells
AT neuenhahnmichael characterizationandclinicalenrichmentofhlac0702restrictedcytomegalovirusspecificcd8tcells